TSGA13 Activators
TSGA13 activators belong to a specialized class of chemical compounds that focus on modulating the activity of the gene product known as Testis Specific Gene A13 (TSGA13). The activators of TSGA13 are designed to increase the expression or activity of this protein. In general, the activation of a gene product can involve up-regulation of gene expression, stabilization of the mRNA transcript, enhancing the translation efficiency, or preventing the degradation of the protein product. The specific mechanisms by which TSGA13 activators achieve their effect can vary significantly depending on the molecular structure of the activator and the cellular context in which it is used.
Chemically, TSGA13 activators could be small organic molecules, peptides, or other biologically active compounds that have been identified through various methods such as high-throughput screening or even serendipitous discovery. The structure-activity relationship (SAR) of these activators is critical, as minor modifications to the chemical structure can lead to significant changes in their ability to activate TSGA13. These activators often interact with the regulatory regions of the gene or with the gene product itself, stabilizing its structure, altering its interactions with other cellular components, or affecting its post-translational modifications. The study of TSGA13 activators is a complex field, as it involves understanding not only the chemical properties of the compounds but also the intricate details of gene regulation and protein biochemistry.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase leading to increased cAMP levels, which can enhance the function of TSGA13 by influencing cAMP-dependent protein kinase A (PKA), thus potentially affecting TSGA13's role in cellular processes. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a nonspecific inhibitor of phosphodiesterases, which increases intracellular cAMP by preventing its breakdown, thereby potentially enhancing TSGA13 activity via PKA activation. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
8-Bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP) is a cAMP analog that activates PKA, which could lead to enhanced TSGA13 activity if TSGA13 is a substrate or is regulated by PKA-dependent pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast is a selective inhibitor of phosphodiesterase types 5 and 6, leading to increased cGMP levels that could enhance TSGA13 function through pathways regulated by cGMP and its associated kinases. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram inhibits phosphodiesterase type 4, resulting in increased cAMP levels, which may upregulate TSGA13 activity via cAMP-dependent signaling mechanisms. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $147.00 | ||
Anagrelide inhibits phosphodiesterase type 3, elevating cAMP and potentially enhancing TSGA13 activity by influencing signaling pathways that are regulated by cAMP levels. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine inhibits phosphodiesterase type 1, thereby increasing cAMP and cGMP levels, which could indirectly enhance TSGA13 function through their respective signaling pathways. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $26.00 $50.00 $99.00 $150.00 $1887.00 | 40 | |
Luteolin is a phosphodiesterase inhibitor that could increase intracellular levels of cAMP, possibly leading to enhanced TSGA13 activity through PKA-dependent signaling pathways. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
Milrinone is a selective phosphodiesterase type 3 inhibitor that increases cAMP levels, which may influence TSGA13 activity through downstream cAMP-dependent signaling pathways. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Cilostamide specifically inhibits phosphodiesterase type 3, resulting in elevated cAMP levels, which could lead to enhanced TSGA13 function by modulating cAMP-dependent signaling cascades. | ||||||